Format

Send to

Choose Destination
J NeuroAIDS. 1996;1(4):79-88.

Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.

Author information

1
, Neurology Research, Warren 408, Massachusetts General Hospital, Fruit Street, Boston, MA, 02114.

Abstract

OBJECTIVE:

To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).

DESIGN:

Open label, uncontrolled study.

SETTING:

Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.

PATIENTS:

Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.

INTERVENTION:

Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.

RESULTS:

None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.

CONCLUSIONS:

Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.

PMID:
16873181
DOI:
10.1300/j128v01n04_08
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center